z-logo
open-access-imgOpen Access
Long Term Exposure to Tenofovir Disoproxil Fumarate-Containing Antiretroviral Therapy Is Associated with Renal Impairment in an African Cohort of HIV-Infected Adults
Author(s) -
Agbaji Oche O.,
Abah Isaac O.,
Ebonyi Augustine O.,
Gimba Zumnan M.,
Abene Esla E.,
Gomerep Simji S.,
Falang Kakjing D.,
Anejo-Okopi Joseph,
Agaba Patricia A.,
Ugoagwu Placid O.,
Agaba Emmanuel I.,
Imade Godwin E.,
Sagay Atiene S.,
Okonkwo Prosper,
Idoko John A.,
Kanki Phyllis J.
Publication year - 2019
Publication title -
journal of the international association of providers of aids care (jiapac)
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.813
H-Index - 31
eISSN - 2325-9582
pISSN - 2325-9574
DOI - 10.1177/2325958218821963
Subject(s) - medicine , interquartile range , regimen , cohort , renal function , tenofovir alafenamide , tenofovir , odds ratio , emtricitabine , logistic regression , antiretroviral therapy , human immunodeficiency virus (hiv) , viral load , immunology
Objectives and Method: There are growing concerns of tenofovir disoproxil fumarate (TDF)–associated renal toxicity. We evaluated the effect of long-term TDF exposure on renal function in a cohort of HIV-1-infected Nigerians between 2006 and 2015. Multivariate logistic regression was used to identify predictors of renal impairment at different time over 144 weeks of antiretroviral therapy (ART).Results: Data of 4897 patients, median age 42 years (interquartile range: 36-49), and 61% females were analyzed. The prevalence of renal impairment increased from 10% at week 24 to 45% at 144 weeks in TDF-exposed participants compared to an increase from 8% at 24 weeks to 14% at 144 weeks in TDF-unexposed participants. Tenofovir disoproxil fumarate exposure predicted the risk of renal impairment at 144 weeks of ART (odds ratio: 2.36; 95% confidence interval: 1.28-4.34).Conclusion: Long-term exposure to TDF-based ART significantly increases the likelihood of renal impairment. The continued use of TDF-based regimen in our setting should be reviewed. We recommend the urgent introduction of tenofovir alafenamide–based regimen in the HIV treatment guidelines of Nigeria and other resource-limited countries.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom